Abstract
Background: Once the optimal dose is reached, subcutaneous immunotherapy [SCIT] with mite extract is capable of reducing symptoms and the need for rescue medication. Objective: To assess the capacity of a subcutaneous extract of mites [D. pteronyssinus] to bring about a reduction in concomitant medication as well as in vivo and in vitro changes in just 2-3 months of treatment in patients with allergic asthma. Methods: A total of 45 patients with persistent mildmoderate allergic asthma due to sensitisation to D. pteronyssinus were included in a multi-centre, double-blind, placebocontrolled trial. Length of treatment was 4 months. After a period for adjusting medication in order to classify asthma severity appropriately, patients were commenced on treatment of 400 or 800 μg/day of budesonide as concomitant medication. Results: After 4 months of treatment there were no significant changes in the budesonide dose between the active group and the placebo group. In the active group there was a significant difference between active and placebo group in sIgG4 [p=.0003], as well as a significant increase in the cutaneous tolerance index [2.81, CI 95%: 1.29 – 7.48, which was significant with a Confidence Interval of 95%]. These changes were not observed in the placebo group. Conclusion: After just 4 months of treatment, SCIT was capable of inducing in vivo and in vitro changes, but these changes were not reflected in improved clinical outcome within the first 4 months of therapy.
Keywords: Allergic asthma, dermatophagoides pteronyssinus, specific IgG4, short-term effect, skin-prick test, subcutaneous immunotherapy
Current Drug Delivery
Title: Assessment of Short-Term Changes Induced by a Dermatophagoides pteronyssinus Extract on Asthmatic Patients. Randomised, Double-Blind, Placebo-Controlled Trial
Volume: 8 Issue: 2
Author(s): Carmen Vidal, Ana I. Tabar, Javier Figueroa, Jose A. Navarro, Cesarea Sanchez, Agustin Orovitg, Margarita Armisen, Susana Echechipia, Alejandro Joral, Susana Lizarza, Mª Teresa Lizaso, Virginia Rodriguez and Fernando de la Torre
Affiliation:
Keywords: Allergic asthma, dermatophagoides pteronyssinus, specific IgG4, short-term effect, skin-prick test, subcutaneous immunotherapy
Abstract: Background: Once the optimal dose is reached, subcutaneous immunotherapy [SCIT] with mite extract is capable of reducing symptoms and the need for rescue medication. Objective: To assess the capacity of a subcutaneous extract of mites [D. pteronyssinus] to bring about a reduction in concomitant medication as well as in vivo and in vitro changes in just 2-3 months of treatment in patients with allergic asthma. Methods: A total of 45 patients with persistent mildmoderate allergic asthma due to sensitisation to D. pteronyssinus were included in a multi-centre, double-blind, placebocontrolled trial. Length of treatment was 4 months. After a period for adjusting medication in order to classify asthma severity appropriately, patients were commenced on treatment of 400 or 800 μg/day of budesonide as concomitant medication. Results: After 4 months of treatment there were no significant changes in the budesonide dose between the active group and the placebo group. In the active group there was a significant difference between active and placebo group in sIgG4 [p=.0003], as well as a significant increase in the cutaneous tolerance index [2.81, CI 95%: 1.29 – 7.48, which was significant with a Confidence Interval of 95%]. These changes were not observed in the placebo group. Conclusion: After just 4 months of treatment, SCIT was capable of inducing in vivo and in vitro changes, but these changes were not reflected in improved clinical outcome within the first 4 months of therapy.
Export Options
About this article
Cite this article as:
Vidal Carmen, I. Tabar Ana, Figueroa Javier, A. Navarro Jose, Sanchez Cesarea, Orovitg Agustin, Armisen Margarita, Echechipia Susana, Joral Alejandro, Lizarza Susana, Teresa Lizaso Mª, Rodriguez Virginia and de la Torre Fernando, Assessment of Short-Term Changes Induced by a Dermatophagoides pteronyssinus Extract on Asthmatic Patients. Randomised, Double-Blind, Placebo-Controlled Trial, Current Drug Delivery 2011; 8 (2) . https://dx.doi.org/10.2174/156720111794479871
DOI https://dx.doi.org/10.2174/156720111794479871 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Recent Advances in the Discovery of Novel Anti-Herpetic Agents from Chinese Herbal Medicines
Current Organic Chemistry Enantioselective Phytotoxicity and the Relative Mechanism of Current Chiral Herbicides
Current Protein & Peptide Science Allergic Contact Dermatitis to Fentanyl TTS with Good Tolerance to Systemic Fentanyl
Recent Patents on Inflammation & Allergy Drug Discovery A New Insight of Herbal Promises Against Ocular Disorders: An Occuloinformatics Approach
Current Topics in Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Carotenoids and Prostate Cancer Risk
Mini-Reviews in Medicinal Chemistry Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry Effects and Mechanisms of Ban-Xia Xie-Xin Decoction on Type 2 Diabetes Mellitus: Network Pharmacology Analysis and Experimental Evidence
Endocrine, Metabolic & Immune Disorders - Drug Targets New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
Current Cardiology Reviews Pharmacogenetics of Selective Serotonin Reuptake Inhibitor Response in Major Depression
Current Pharmacogenomics Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets